Lucid Diagnostics Statistics
Share Statistics
Lucid Diagnostics has 108.19M
shares outstanding. The number of shares has increased by 65.7%
in one year.
| Shares Outstanding | 108.19M |
| Shares Change (YoY) | 65.7% |
| Shares Change (QoQ) | 46.36% |
| Owned by Institutions (%) | 6.57% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 13,211 |
| FTD / Avg. Volume | 1.14% |
Short Selling Information
The latest short interest is 1.78M, so 1.75% of the outstanding
shares have been sold short.
| Short Interest | 1.78M |
| Short % of Shares Out | 1.75% |
| Short % of Float | 2.74% |
| Short Ratio (days to cover) | 2 |
Valuation Ratios
The PE ratio is -0.91 and the forward
PE ratio is -4.78.
Lucid Diagnostics's PEG ratio is
0.02.
| PE Ratio | -0.91 |
| Forward PE | -4.78 |
| PS Ratio | 9.52 |
| Forward PS | 3.4 |
| PB Ratio | 0.01 |
| P/FCF Ratio | -0.92 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Lucid Diagnostics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1069.04,
with a Debt / Equity ratio of 0.
| Current Ratio | 1069.04 |
| Quick Ratio | 1069.02 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.48 |
| Debt / FCF | -0.47 |
| Interest Coverage | -1771.23 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $60,361.11 |
| Profits Per Employee | $-632,347.22 |
| Employee Count | 72 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 20.82 |
Taxes
| Income Tax | 7.5B |
| Effective Tax Rate | -16464.23% |
Stock Price Statistics
The stock price has increased by 67.6% in the
last 52 weeks. The beta is 1.28, so Lucid Diagnostics's
price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | 67.6% |
| 50-Day Moving Average | 1.36 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 64.11 |
| Average Volume (20 Days) | 1,156,372 |
Income Statement
In the last 12 months, Lucid Diagnostics had revenue of 4.35M
and earned -45.53M
in profits. Earnings per share was -0.75.
| Revenue | 4.35M |
| Gross Profit | -3.92M |
| Operating Income | -46.05M |
| Net Income | -45.53M |
| EBITDA | -44.34M |
| EBIT | -45.5M |
| Earnings Per Share (EPS) | -0.75 |
Full Income StatementBalance Sheet
The company has 22.36M in cash and 21.25M in
debt, giving a net cash position of 1.1M.
| Cash & Cash Equivalents | 22.36M |
| Total Debt | 21.25M |
| Net Cash | 1.1M |
| Retained Earnings | -203.77B |
| Total Assets | 32.8B |
| Working Capital | -9.03B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -44.14M
and capital expenditures -646K, giving a free cash flow of -44.79M.
| Operating Cash Flow | -44.14M |
| Capital Expenditures | -646K |
| Free Cash Flow | -44.79M |
| FCF Per Share | -0.89 |
Full Cash Flow StatementMargins
Gross margin is -90.2%, with operating and profit margins of -1059.64% and -1047.61%.
| Gross Margin | -90.2% |
| Operating Margin | -1059.64% |
| Pretax Margin | -1047.61% |
| Profit Margin | -1047.61% |
| EBITDA Margin | -1020.16% |
| EBIT Margin | -1059.64% |
| FCF Margin | -1030.51% |
